These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 30808814)

  • 1. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
    Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
    Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
    Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
    Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
    Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
    Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of treatment failure in chronic lymphocytic leukemia patients.
    Wang S; Lafeuille MH; Lefebvre P; Romdhani H; Emond B; Senbetta M
    Curr Med Res Opin; 2018 Jun; 34(6):1135-1142. PubMed ID: 29649904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
    McBride A; Daniel S; Driessen MT; Szende A; Choudhry A; Tian M; Ariely R; Thompson S
    Leuk Res; 2021 Dec; 111():106671. PubMed ID: 34530254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
    Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
    Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pigmentary traits, sun exposure, and risk of non-Hodgkin's lymphoma/chronic lymphocytic leukemia: A study within the French E3N prospective cohort.
    Garcin LM; Gelot A; Gomez RR; Gusto G; Boutron-Ruault MC; Kvaskoff M; Severi G; Besson C
    Cancer Med; 2021 Jan; 10(1):297-304. PubMed ID: 33219744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia.
    Lee TY; Johnson A; Cooke CE; Yared JA; Summers A; Yang K; Liu S; Tang B; Onukwugha E
    J Manag Care Spec Pharm; 2024 May; 30(5):430-440. PubMed ID: 38701030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Dashputre AA; Gatwood KS; Gatwood J
    J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.
    Chang TW; Weaver AL; Shanafelt TD; Habermann TM; Wriston CC; Cerhan JR; Call TG; Brewer JD
    Int J Dermatol; 2017 Nov; 56(11):1125-1129. PubMed ID: 28685851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Famenini S; Martires KJ; Zhou H; Xavier MF; Wu JJ
    J Am Acad Dermatol; 2015 Jan; 72(1):78-84. PubMed ID: 25440434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands.
    Uyl-de Groot CA; Okhuijsen SY; Hagenbeek A; Huijgens PC; van Imhoff GW; Löwenberg B; Verdonck LF; Rutten FF
    Bone Marrow Transplant; 1995 Apr; 15(4):605-10. PubMed ID: 7655388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
    Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
    Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment.
    Kutikova L; Bowman L; Chang S; Long SR; Arning M; Crown WH
    Leuk Lymphoma; 2006 Aug; 47(8):1535-44. PubMed ID: 16966264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.